How many clinical trials are studying Orforglipron?

7 recruiting trials in our tracked data involve Orforglipron.

What conditions is Orforglipron being studied for?

In our tracked recruiting trials, Orforglipron is being studied in trials for Obesity, Overweight, Atherosclerosis Cardiovascular Disease.

Orforglipron: clinical trials recruiting now

Q: Is Orforglipron FDA-approved?

Yes. According to the FDA drug label available through openFDA, Orforglipron is an FDA-approved drug. Its FDA label carries a boxed warning.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Orforglipron appears in the FDA drug-label database. Marketed as FOUNDAYO.
Boxed warning: The FDA label for Orforglipron carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.

FDA label via openFDA

Phase breakdown

Phase 1 1 Phase 3 6

Conditions being studied

Condition	Trials
Obesity · Orforglipron for Obesity	5
Overweight · Orforglipron for Overweight	3
Atherosclerosis Cardiovascular Disease	1
Behavior	1
Chronic Kidney Disease	1
Diabetes Melletus	1
Diabetes Mellitus, Type 2	1
Endocrine System Diseases	1
Fasting	1
Feeding Behavior	1
Glucagon-Like Peptide Receptors	1
Glucagon-Like Peptide-1 Receptor	1
Glucose Metabolism Disorders	1
Healthy Participants	1
Membrane Proteins	1

Recruiting trials involving Orforglipron

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 117 locations
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 34 locations
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
NCT07613307 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 40 locations
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 566 locations
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 136 locations
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
NCT07793019 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location

Common questions

Is Orforglipron FDA-approved?

Yes, marketed as FOUNDAYO. Its FDA label carries a boxed warning.

How many recruiting trials involve Orforglipron?

7 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.